Phase I trial of bortezomib (PS-341) in combination with docetaxel in patients with advanced solid tumors

TNF potentiates anticancer activity of bortezomib (Velcade®) through reduced expression of proteasome subunits and dysregulation of unfolded protein response

“…[14][15][16] Combination of bortezomib with other therapeutic agents such as DNA-damaging agents, Hsp90 inhibitor 17-AAG or lenalidomide has been used in some systems to overcome bortezomib resistance. 2 Several clinical trials have been already performed, 17,18 while new preclinical studies are aimed at identifying new drug combinations suitable to be tested in the clinic. The efficacy of bortezomib against different types of cancer has been shown to be increased by e.g.…”

“…radiotherapy, doxorubicin, gemcitabine, carboplatin, cyclophosphamide, tunicamycin, cyclooxygenase and farnesyl transferase inhibitors. [17][18][19][20][21][22][23] Several cytokines, including tumor necrosis factor (TNF), have been tested as anticancer agents either alone or in combination with common chemotherapeutics. 24 TNF is used in the clinic for isolated limb perfusion in patients suffering from advanced soft tissue sarcomas and melanomas 25,26 or for isolated perfusion of metastases.…”